HighTower Advisors’s Novo Nordisk NVO Stock Holding History

HighTower Advisors’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$418	–	3872
2025 Q3	$418	Buy	+100	New	+$5.85K	﹤0.01%	3781
2024 Q1	–	Sell	-1,100	Closed	-$37K	–	3893
2023 Q4	$37K	Buy	1,100 +340	+45%	+$33.6K	﹤0.01%	3346
2023 Q3	$128K	Buy	760 +750	+7,500%	+$66.1K	﹤0.01%	3039
2023 Q2	$15.7K	Buy	+10	New	+$817	﹤0.01%	3268
2022 Q1	–	Sell	-26	Closed	-$4K	–	3596
2021 Q4	$4K	Buy	+26	New	+$1.41K	﹤0.01%	3208

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

HighTower Advisors's NVO Position: Q2 2026 in Review

HighTower Advisors increased its Novo Nordisk (NVO) stake by 72% in Q2 2026, buying an estimated $7.23M and bringing the position to 403,262 shares worth $19.3M. The position accounts for 0.02% of the portfolio, ranked #659.

HighTower Advisors first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $72.9M in Q2 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

HighTower Advisors held 403,262 shares of Novo Nordisk worth $19.3M as of Q2 2026.
HighTower Advisors bought 168,196 Novo Nordisk shares in Q2 2026, an estimated $7.23M.
Novo Nordisk made up 0.02% of HighTower Advisors's portfolio in Q2 2026, its #659 holding.
HighTower Advisors first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
HighTower Advisors's Novo Nordisk position peaked at $72.9M in Q2 2024.
1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.